新疆维吾尔族、哈萨克族高血压患者血管紧张素转换酶基因I/D多态性与血管紧张素转化酶抑制剂降压疗效的关系  

Relationship between angiotensin-converting enzyme gene I/D polymorphism and antihypertensive efficacy of ACE inhibitors in hypertensive patients of Uyghur and Kazak in Xinjiang

作　　者：谷兰平 徐新娟[1] 张荣秀 

机构地区：[1]新疆医科大学第一附属医院高血压科,乌鲁木齐830054

出　　处：《中华诊断学电子杂志》2017年第4期225-229,共5页Chinese Journal of Diagnostics(Electronic Edition)

基　　金：新疆维吾尔自治区科技支撑计划(201533104)

摘　　要：目的探讨血管紧张素转换酶(ACE)基因I/D多态性,在新疆维吾尔族、哈萨克族原发性高血压患者的差异与血管紧张素转换酶抑制剂(ACEI)降压疗效的关系。方法选取2015年11月至2017年4月于新疆医科大学第一附属医院高血压科就诊的394例原发性高血压患者,其中维吾尔族191例,哈萨克族203例。采用基因多态性检测试剂盒(PCR-荧光探针技术)对ACE I/D基因型等进行检测,对两组降压疗效、不良反应进行分析。统计学处理采用SPSS 17.0处理,相关危险因素采用非条件Logistic回归分析。结果 394例三种基因型患者对ACEI类药物疗效正常敏感性、高敏感性例数分别为137,257例,频率为34.77%、65.23%。其中维吾尔族分别为33.51%(64/191)、66.49%(127/191),哈萨克族分别为35.96%(73/203)、64.04%(130/203),两民族的ACE I/D基因多态性与ACEI类药物疗效差异无统计学意义(χ~2=0.26,P>0.05)。394例三种基因型患者对ACEI类药物不良反应明显增加的例数为81例,频率为20.56%,其中维吾尔族患者为19.37%(37/191),哈萨克族患者为21.67%(44/203),两民族对ACEI类药物不良反应差异无统计学意义(χ~2=0.32,P>0.05)。非条件Logistic回归分析显示,ACE I/D的民族差异与ACEI类药物疗效无相关性(OR=0.69,P>0.05)。结论 ACE I/D基因多态性在新疆哈萨克族、维吾尔族原发性高血压患者的民族差异与ACEI类药物疗效无相关性。Objective To investigate the correlation between the angiotensin-converting enzyme（ACE） gene I / D polymorphism and prospective antihypertensive efficacy of ACE inhibitors （ ACEI） inXinjiang,Kazak,Uyghur patients with essential hypertension.Methods From November 2015 to April 2017,394 patients with primary hypertension in the first Affiliated Hospital of Xinjiang Medical University wereenrolled,including 191 Uyghur cases, 203 Kazak cases. The efficacy of ACE I / D genotype, ACEI drugefficacy,and adverse events were detected by the Gene Polymorphism Test Kit （ PCR-fluorescence ProbeTechnique）.The antihypertensive efficacy and adverse reactions of ACEI were analyzed.Results Among the394 patients,the number of normal sensitivity and high sensitivity to ACEI were 137 and 257 respectively.Thefrequency were 34.77%and 65.23%.Uyghur nationality were 33.51%（ 64 / 191） and 66.49%（ 127 / 191）,Kazak patients were 35. 96% （ 73 / 203） and 64. 04% （ 130 / 203）, respectively. There was no significantdifference between the two groups（χ2= 0.26,P 〉 0.05）. In 394 patients,the number of adverse drug reactionsto ACEI was 81,and the frequency significantly increased by 20.56%,of which 19.37%（37 / 191） in Kazakand 21.67%（44 / 203） in Uyghur. There was no significant difference between the two nationalities in theadverse reactions of ACEI （χ2= 0.32,P 〉0.05）.Logistic regression analysis showed that ethnic differences inACE I / D had no association with the efficacy of ACEI （OR = 0. 69, P 〉 0. 05）.Conclusion There is nocorrelation between ACE gene I / D polymorphism in Xinjiang Kazak and Uygur patients with essentialhypertension and the curative effect of ACEI.

关 键 词：血管紧张素转换酶 原发性高血压 疗效 

分 类 号：R544.1[医药卫生—心血管疾病]